NANJING, China, Oct. 30, 2024 /PRNewswire/ — Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has […]
NANJING, China, Oct. 25, 2024 /PRNewswire/ — On October 24, 2024, TASTE-2, a Chinese innovative stroke drug study led by Professor Wang Yongjun from Beijing Tiantan Hospital, was published in an oral report at the 16th […]
– Designación de terapia innovadora para los comprimidos sublinguales de Sanbexin otorgada por la Administración de Alimentos y Medicamentos de Estados Unidos NANJING, China, 16 de septiembre de 2024 /PRNewswire/ — El 2 de septiembre […]
NANJING, Chine, 16 septembre 2024 /PRNewswire/ — Le 2 septembre 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) a annoncé que comprimés sublinguaux de sanbexine (comprimés sublinguaux édaravone et dexborneol), un médicament innovant contre les accidents vasculaires […]
NANJING, China, 16. September 2024 /PRNewswire/ — Am 2. September 2024 gab Simcere Pharmaceuticals Group Ltd. (2096.HK) bekannt, dass die Sanbexin-Sublingualtabletten (Edaravone- und Dexborneol-Sublingualtabletten), ein innovatives Medikament gegen Schlaganfall, von der US-amerikanischen Food and Drug […]
